Catamaran Corp (CTRX) 61.47 $CTRX UnitedHealth Group

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Catamaran Corp (CTRX) 61.47 $CTRX

UnitedHealth Group boosts quarterly dividend, again
AP - Wed Jun 08, 7:50AM CDT
NEW YORK (AP) — UnitedHealth, the nation's largest health insurer, is boosting its quarterly dividend by 25 percent, citing growth.
ANTM: 123.36 (-1.72), CTRX: 61.47 (+0.04), ANTX: 42.56 (-0.37), UNH: 135.74 (-0.31), CCT.TO: 80.18 (+0.12), AET: 116.16 (-0.96)


UnitedHealth ups 2016 outlook after surprisingly strong 1Q
By TOM MURPHY - AP - Tue Apr 19, 7:52AM CDT
UnitedHealth hiked its 2016 forecast after the nation's largest health insurer topped Wall Street's first-quarter earnings expectations.
CTRX: 61.47 (+0.04), UNH: 135.74 (-0.31), CCT.TO: 80.18 (+0.12)

Japan Slows Down, Oil Falls – Expect Weakness In The Markets This Morning
Dana Blankenhorn - Amigobulls - Mon Aug 17, 2:06AM CDT
The Japanese economy contracted - oil prices fell further. Slowing growth in Germany, shaky sentiment around China spread gloom in the markets this morning.
AMZN: 770.62 (+1.46), GE: 31.20 (-0.04), CTRX: 61.47 (+0.04), FB: 126.17 (+0.05), UNH: 135.74 (-0.31), AET: 116.16 (-0.96), GOOG: 768.78 (+1.73), HUM: 176.53 (-2.18), CELG: 106.37 (-0.37), CI: 127.64 (-0.62), NFLX: 97.38 (-0.07), AGN: 237.76 (+3.22), ANTM: 123.36 (-1.72), ESRX: 72.22 (-0.48), CVS: 93.37 (-0.03), GOOGL: 791.40 (+1.55), AAPL: 106.73 (+0.63)


Aetna turns in better-than-expected 2Q, hikes forecast again
By TOM MURPHY - AP - Tue Aug 04, 12:07PM CDT
Aetna's second-quarter earnings jumped 33 percent and the health insurer raised its 2015 forecast again after receiving a boost from a government business it plans to feed with a roughly $35 billion acquisition.
CI: 127.64 (-0.62), CNC: 67.34 (-0.95), ANTM: 123.36 (-1.72), CTRX: 61.47 (+0.04), UNH: 135.74 (-0.31), ANTX: 42.56 (-0.37), CCT.TO: 80.18 (+0.12), AET: 116.16 (-0.96), HNT: 67.19 (+2.38), HUM: 176.53 (-2.18)

OptumRx, Catamaran Complete Combination
M2 - Fri Jul 24, 9:35AM CDT
NEW YORK-- Optum announced the completion of its combination with Catamaran Corporation [NASDAQ: CTRX, TSX: CCT]. Catamaran and Optum's pharmacy care services business, OptumRx, are expected to serve the needs of more than 65 million people and fulfill more than one billion prescriptions in 2015.
CTRX: 61.47 (+0.04)

Catamaran Corporation to be Removed From the NASDAQ-100 Index Beginning July 24, 2015
GlobeNewswire - Thu Jul 23, 1:27PM CDT
Nasdaq (Nasdaq:NDAQ) announces that Catamaran Corporation (Nasdaq:CTRX) will be removed from the NASDAQ-100 Index (Nasdaq:NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq:NDXE) and the NASDAQ-100 Ex-Technology Index (Nasdaq:NDXX) prior to market open on Friday, July 24, 2015. Catamaran had previously announced that its shareholders approved the acquisition of Catamaran in a cash transaction.
CTRX: 61.47 (+0.04), NDAQ: 71.64 (+0.43)

A.M. Best Assigns Issue Ratings to UnitedHealth Group Incorporated's New Senior Unsecured Notes
BusinessWire - Thu Jul 23, 11:34AM CDT
A.M. Best has assigned an issue rating of "bbb+" to the recently issued senior unsecured notes of UnitedHealth Group Incorporated (UnitedHealth) (Minnetonka, MN) [NYSE:UNH]. The outlook assigned to all ratings is stable. The existing ratings of UnitedHealth and its subsidiaries are unchanged. (See below for a detailed list of the issue ratings.)
CTRX: 61.47 (+0.04), UNH: 135.74 (-0.31)

Fitch Rates UnitedHealth Group's Planned Issuance 'A-(EXP)'
BusinessWire - Mon Jul 20, 8:48AM CDT
Fitch Ratings has assigned an 'A-(EXP)' rating to UnitedHealth Group Incorporated's (UNH) planned issue of senior unsecured notes various maturities. The ratings are equivalent to Fitch's ratings on UNH's currently outstanding senior unsecured notes.
CTRX: 61.47 (+0.04)


UnitedHealth tops Street 2Q forecasts, raises forecasts
By TOM MURPHY - AP - Thu Jul 16, 10:43AM CDT
UnitedHealth continued to juice up its business outside health insurance in a better-than-expected second quarter while rivals scrambled to add enrollment in a wave of mega-mergers sweeping the sector.
CNC: 67.34 (-0.95), CI: 127.64 (-0.62), ANTM: 123.36 (-1.72), CTRX: 61.47 (+0.04), ANTX: 42.56 (-0.37), UNH: 135.74 (-0.31), CCT.TO: 80.18 (+0.12), AET: 116.16 (-0.96), HUM: 176.53 (-2.18)

Catamaran Shareholders Approve Acquisition by UnitedHealth Group
PR Newswire - Tue Jul 14, 4:00PM CDT
Catamaran Corporation [NASDAQ: CTRX, TSX: CCT] announced that at a special meeting of its shareholders held earlier today, Catamaran shareholders approved the previously announced arrangement agreement and plan of arrangement providing for the acquisition of Catamaran by UnitedHealth Group [NYSE: UNH].
CTRX: 61.47 (+0.04), UNH: 135.74 (-0.31), CCT.TO: 80.18 (+0.12)

Catamaran and Health New England Partnership Reduces Same-Cause Hospital Readmissions by More Than 70 Percent
CNW Group - Thu Jun 25, 9:00AM CDT
One-year program results demonstrate the importance of transitional medication therapy management
CTRX: 61.47 (+0.04), CCT.TO: 80.18 (+0.12)

The Law Office of Robbins Arroyo LLP Announces that It Has Filed a Class Action Lawsuit Against Catamaran Corporation (CTRX)
PR Newswire - Wed Jun 03, 4:08PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that it filed a class action lawsuit on June 3, 2015, in the U.S. District Court for the Northern District of Illinois, Eastern Division (the "Court" on behalf of the shareholders of Catamaran Corporation ("Catamaran" (NASDAQGS: CTRX) against Catamaran and its Board of Directors (the "Board" for, among other things, violations of sections 14(a) and 20(a) of the Securities and Exchange Act of 1934 (the "Exchange Act" and U.S. Securities and Exchange Commission Rule 14a-9 promulgated thereunder.
CTRX: 61.47 (+0.04)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 352

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 377

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Scent Dispensing Solution for Hunting Enthusiasts

Updated Category News Views 168

Introducing a Game-Changing Scent Dispensing System In the world of hunting, attracting game animals can often be a challenge. A new invention, designed specifically for this purpose, promises to make the process much simpler and more efficient. The inventor of this innovative scent dispensing system, THE DRAG LINE PRO, envisioned a better way to utilize a scent drag...

Continue Reading
Corby Spirit and Wine Limited Reports Impressive Fiscal Results

Updated Category News Views 295

Corby Spirit and Wine Limited Announces Strong Fiscal Performance Corby Spirit and Wine Limited, renowned for its position as a leading Canadian manufacturer, marketer, and importer of spirits, has recently unveiled impressive results for its fourth quarter and full-year fiscal 2025. The company demonstrated significant growth in revenue, achieving total revenues of...

Continue Reading
Sezzle Faces Setback as Short-Seller Targets Its Practices

Updated Category News Views 113

Sezzle's Stock Takes a Dramatic Hit Recently, the buy now, pay later (BNPL) provider Sezzle experienced a significant decrease in its stock value. Reports indicate that shares fell over 28.6% in early trading after Hindenburg Research disclosed a short position against the company due to concerns surrounding risky lending practices. Understanding the Short-Selling...

Continue Reading
Exploring the Growth of $1000 in Marsh & McLennan Cos Today

Updated Category News Views 116

Understanding Long-Term Investment in Marsh & McLennan Marsh & McLennan Cos (NYSE: MMC) has established itself as a financial powerhouse, outperforming the market consistently over the past two decades. Investors have experienced an impressive annualized return of 13.31%, showcasing the benefits of long-term investment strategies. The Value of Persistence in Investing...

Continue Reading
Discover Toll Brothers' Latest Luxury Homes at Overbrook Estates

Updated Category News Views 671

Introducing Overbrook Estates by Toll Brothers Toll Brothers, Inc. (NYSE:TOL), a renowned name in luxury homebuilding, excitedly unveils its newest community: Overbrook Estates. This anticipated project is set to grace the Huntersville area, offering homebuyers elegant living in a master-planned environment. Positioned conveniently off Highway 77, this prime location sets...

Continue Reading